AstraZeneca PLC Files 9M and Q3 2025 Results

TL;DR

AZN dropped Q3 results, check the 6-K for deets.

AI Summary

AstraZeneca PLC filed a Form 6-K on November 6, 2025, reporting its 9-month and Q3 2025 results. The filing is a report of a foreign issuer and indicates that AstraZeneca files annual reports under Form 20-F. The company's address is in Cambridge, United Kingdom.

Why It Matters

This filing provides investors with AstraZeneca's latest financial performance for the first nine months and third quarter of 2025, crucial for assessing the company's ongoing health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial results filing and does not contain new or unusual risk factors.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — SEC File Number
• 20251106 (date) — Filing date
• November 2025 (date) — Reporting period
• 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (company) — Company address

FAQ

Key Financial Figures

• $43,236 — 0; ● Total Revenue up 11% to $43,236m, driven by growth in all Therapy Areas
• $7.04 — ● Core EPS increased 15% to $7.04 ● 16 positive Phase III read
• $4.5b — otprint having broken ground at our new $4.5bn Virginia manufacturing facility in Oct
• $50b — s part of the Company's plans to invest $50bn in US manufacturing and R&D by 2030, a
• $15m — ks), following an initial investment of $15m made in Q2 2024. $170m was paid on
• $170m — nvestment of $15m made in Q2 2024. $170m was paid on closing, $30m to be paid af
• $30m — 2 2024. $170m was paid on closing, $30m to be paid after two years and up to a
• $100m — aid after two years and up to a further $100m is payable on achievement of regulatory
• $150 million — 2F;Merck received an upfront payment of $150 million and will receive deferred payments tota
• $400m — ceive deferred payments totalling up to $400m. In addition, Merck is eligible
• $175m — 202F;Merck is eligible to receive up to $175m in potential approval milestones and up
• $235m — potential approval milestones and up to $235m in sales milestone payments, plus singl

Filing Documents

• a4030g.htm (6-K) — 1647KB
• 0001654954-25-012630.txt ( ) — 1649KB

Financial Statements

Financial Statements.   6.  Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, is recorded in Other operating income and expense in the Group's

financial statements

financial statements.     Revenue drivers   Table 3: Product Revenue by medicine                                                    9M 2025            % Change Q3 2025            % Change                                                                                                                 $m   % Total   Actual   CER   $m   % Total   Actual   CER   Tagrisso 5,352  12  10  10  1,864  12  11  10  Imfinzi 4,317  10  25  25  1,601  11  33  31  Calquence 2,551  6  10  10  916  6  13  11  Lynparza 2,401  6  8  7  837  6  7  5  Enhertu 1,976  5  37  38  714  5  40  39  Zoladex 884  2  5  6  296  2  7  6  Truqap 495  1  85  85  193&

View Full Filing

View this 6-K filing on SEC EDGAR